New approaches to the discovery of treatments for major unmet medical needs
Phenotypic drug discovery (PDD) has lower costs and is showing higher success rates than traditional target-based approaches, improving health outcomes and lowering the cost of new medications - see more. Our multidisciplinary research group is undertaking PDD in areas of cancer, fibrosis (organ failure) and autoimmune disease. Contact Associate Professor Bernard Flynn for more project details.